{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218018","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.727348+00:00","generated_at":"2026-06-24T00:56:11.429266+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track","bullets":["Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).","Cash and investments $162.9M as of June 30, 2022; estimated runway into Q2 2024.","Transition to transient transfection manufacturing for SGT-001; expects to continue dosing patients in 2023.","Next-gen candidate SGT-003 on track for mid-2023 IND submission; capsid shows improved muscle tropism vs AAV9.","Long-term data from IGNITE DMD trial of SGT-001 expected in early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218018","json":"https://secwatch.observer/filing/0001193125-22-218018.json","markdown":"https://secwatch.observer/filing/0001193125-22-218018.md","text":"https://secwatch.observer/filing/0001193125-22-218018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/0001193125-22-218018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/d385975d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:56:11.429266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}